<p>摩根大通在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在 BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - 免费报告) 的持仓削减了 49.1%。该公司在此期间售出了 47,002 股后，持有 48,812 股 BeOne Medicines 的股票。摩根大通在 BeOne Medicines 的持股在最近的报告期末价值为 16,630,000 美元。</p>
<p>获取 <strong>BeOne Medicines</strong> 警报：</p>
<ul>
<li>硅谷银行的 4 只现金持有量巨大的股票</li>
</ul>
<p>其他机构投资者和对冲基金也增加或减少了在该公司的股份。PNC 金融服务集团在第二季度购买了价值 228,000 美元的 BeOne Medicines 新股份。Geode Capital Management LLC 在第二季度购买了价值约 8,622,000 美元的 BeOne Medicines 新股份。Creative Planning 在第二季度购买了价值约 1,448,000 美元的 BeOne Medicines 新股份。Cetera Investment Advisers 在第二季度购买了价值约 455,000 美元的 BeOne Medicines 新股份。最后，Legal &amp; General Group Plc 在第二季度购买了价值约 13,857,000 美元的 BeOne Medicines 新股份。对冲基金和其他机构投资者持有该公司 48.55% 的股票。</p>
<h2>内部买卖</h2>
<p>在相关消息中，SVP Chan Henry Lee 于 3 月 11 日星期三出售了 341 股公司的股票。该股票以每股 300.00 美元的平均价格出售，总交易额为 102,300.00 美元。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。内部人士在过去三个月内共出售了价值 902,792 美元的 2,665 股公司股票。目前，6.62% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师观点</h2>
<p>几位研究分析师最近对该股票发布了报告。Sanford C. Bernstein 将 BeOne Medicines 的股票评级从 “持有” 上调至 “跑赢大盘”，并在 1 月 12 日的研究报告中设定了 414.00 美元的目标价格。Weiss Ratings 在 1 月 21 日的研究报告中重申了对 BeOne Medicines 的 “卖出（d-）” 评级。Guggenheim 在 2 月 27 日的报告中将 BeOne Medicines 的目标价格从 400.00 美元上调至 410.00 美元，并给予该股票 “买入” 评级。Jefferies Financial Group 将 BeOne Medicines 的评级从 “买入” 下调至 “持有”，并在 3 月 16 日的研究报告中将该股票的目标价格从 420.00 美元下调至 290.00 美元。最后，巴克莱在 2 月 27 日的报告中将 BeOne Medicines 的目标价格从 394.00 美元上调至 405.00 美元，并给予该公司 “增持” 评级。十位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价格为 389.18 美元。</p>
<p><strong>查看我们关于 BeOne Medicines 的最新报告</strong></p>
<h2>BeOne Medicines 股价上涨 2.8%</h2>
<p>ONC 股票在周四开盘时为 283.45 美元。该公司的流动比率为 3.41，速动比率为 3.08，债务与股本比率为 0.22。BeOne Medicines Ltd. - Sponsored ADR 的 12 个月低点为 196.45 美元，12 个月高点为 385.22 美元。该股票的市值为 311 亿美元，市盈率为 112.48，贝塔系数为 0.53。该公司的 50 日移动平均线为 326.25 美元，200 日移动平均线为 327.68 美元。</p>
<p>BeOne Medicines (NASDAQ:ONC - 获取免费报告) 最近在 2 月 26 日星期四公布了其财报。该公司报告本季度每股收益为 0.58 美元，低于分析师一致预期的 1.60 美元，差额为 1.02 美元。该公司本季度的收入为 15 亿美元，而分析师预期为 14.5 亿美元。BeOne Medicines 的净利润率为 5.37%，股本回报率为 10.70%。研究分析师预计 BeOne Medicines Ltd. - Sponsored ADR 在本年度将发布 -5.82 美元的每股收益。</p>
<h2>BeOne Medicines 概况</h2>
<p>（免费报告）</p>
<p>BeOne Medicines Ltd. 是一家总部位于瑞士的全球肿瘤学公司，致力于发现和开发更具可负担性和可及性的创新治疗方案，以帮助全球癌症患者。该公司的产品组合涵盖血液学和实体肿瘤，BeOne 正在通过其内部能力和合作加速其多样化的新型治疗管线的开发。该公司由 Xiao Dong Wang 和 John V. Oyler 于 2010 年 10 月 28 日创立，总部位于瑞士巴塞尔。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 BeOne Medicines</li>
</ul>
<p><strong>想看看其他对冲基金持有的 ONC 股票吗？</strong> 访问 HoldingsChannel.com 获取 BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - 免费报告) 的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T05D?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T05D"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 BeOne Medicines 吗？</h2>
<p>在考虑投资 BeOne Medicines 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 BeOne Medicines 并不在名单上。</p>
<p>虽然 BeOne Medicines 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普全球医疗股指数 ETF - iShares

医疗业 ETF - Vanguard

纽交所高增长板生物技术指数 ETF - First Trust

<p>摩根大通减少了对 BeOne Medicines Ltd. 的持股比例，第三季度减持了 49.1%，出售了 47,002 股，剩余持股为 48,812 股，价值 1,663 万美元。其他机构投资者也调整了他们的持仓。分析师对该股票的评级意见不一，普遍共识为 “适度买入”，平均目标价为 389.18 美元。BeOne Medicines 的股票开盘价为 283.45 美元，市值为 311 亿美元，市盈率为 112.48。该公司报告每股收益为 0.58 美元，未达到预期，并预计本年度每股亏损为 5.82 美元</p>

<p>JPMorgan Chase &amp; Co. trimmed its position in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) by 49.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 48,812 shares of the company's stock after selling 47,002 shares during the period. JPMorgan Chase &amp; Co.'s holdings in BeOne Medicines were worth $16,630,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>摩根大通在最近向证券交易委员会提交的 13F 表格中表示，在第三季度将其在 BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - 免费报告) 的持仓削减了 49.1%。该公司在此期间售出了 47,002 股后，持有 48,812 股 BeOne Medicines 的股票。摩根大通在 BeOne Medicines 的持股在最近的报告期末价值为 16,630,000 美元。</p>
</div><p>Get <strong>BeOne Medicines</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>BeOne Medicines</strong> 警报：</p>
</div><ul>
<li>4 Stocks With Huge Cash Holdings at Silicon Valley Bank</li>
</ul>
<div class="lb-trans"><ul>
<li>硅谷银行的 4 只现金持有量巨大的股票</li>
</ul>
</div><p>Other institutional investors and hedge funds have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at $228,000. Geode Capital Management LLC purchased a new position in shares of BeOne Medicines in the 2nd quarter worth about $8,622,000. Creative Planning bought a new position in BeOne Medicines in the 2nd quarter worth about $1,448,000. Cetera Investment Advisers bought a new position in BeOne Medicines in the 2nd quarter worth about $455,000. Finally, Legal &amp; General Group Plc purchased a new stake in BeOne Medicines during the 2nd quarter valued at about $13,857,000. Hedge funds and other institutional investors own 48.55% of the company's stock.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金也增加或减少了在该公司的股份。PNC 金融服务集团在第二季度购买了价值 228,000 美元的 BeOne Medicines 新股份。Geode Capital Management LLC 在第二季度购买了价值约 8,622,000 美元的 BeOne Medicines 新股份。Creative Planning 在第二季度购买了价值约 1,448,000 美元的 BeOne Medicines 新股份。Cetera Investment Advisers 在第二季度购买了价值约 455,000 美元的 BeOne Medicines 新股份。最后，Legal &amp; General Group Plc 在第二季度购买了价值约 13,857,000 美元的 BeOne Medicines 新股份。对冲基金和其他机构投资者持有该公司 48.55% 的股票。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, SVP Chan Henry Lee sold 341 shares of the company's stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total transaction of $102,300.00. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 2,665 shares of company stock worth $902,792 in the last three months. 6.62% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，SVP Chan Henry Lee 于 3 月 11 日星期三出售了 341 股公司的股票。该股票以每股 300.00 美元的平均价格出售，总交易额为 102,300.00 美元。该交易已在向证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站获取。内部人士在过去三个月内共出售了价值 902,792 美元的 2,665 股公司股票。目前，6.62% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research analysts have recently issued reports on the stock. Sanford C. Bernstein upgraded shares of BeOne Medicines from a &#34;hold&#34; rating to an &#34;outperform&#34; rating and set a $414.00 target price on the stock in a research note on Monday, January 12th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of BeOne Medicines in a research note on Wednesday, January 21st. Guggenheim lifted their target price on BeOne Medicines from $400.00 to $410.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, February 27th. Jefferies Financial Group cut BeOne Medicines from a &#34;buy&#34; rating to a &#34;hold&#34; rating and decreased their price target for the stock from $420.00 to $290.00 in a research note on Monday, March 16th. Finally, Barclays upped their price target on BeOne Medicines from $394.00 to $405.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, February 27th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $389.18.</p>
<div class="lb-trans"><p>几位研究分析师最近对该股票发布了报告。Sanford C. Bernstein 将 BeOne Medicines 的股票评级从 “持有” 上调至 “跑赢大盘”，并在 1 月 12 日的研究报告中设定了 414.00 美元的目标价格。Weiss Ratings 在 1 月 21 日的研究报告中重申了对 BeOne Medicines 的 “卖出（d-）” 评级。Guggenheim 在 2 月 27 日的报告中将 BeOne Medicines 的目标价格从 400.00 美元上调至 410.00 美元，并给予该股票 “买入” 评级。Jefferies Financial Group 将 BeOne Medicines 的评级从 “买入” 下调至 “持有”，并在 3 月 16 日的研究报告中将该股票的目标价格从 420.00 美元下调至 290.00 美元。最后，巴克莱在 2 月 27 日的报告中将 BeOne Medicines 的目标价格从 394.00 美元上调至 405.00 美元，并给予该公司 “增持” 评级。十位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，平均目标价格为 389.18 美元。</p>
</div><p><strong>View Our Latest Report on BeOne Medicines</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 BeOne Medicines 的最新报告</strong></p>
</div><h2>BeOne Medicines Trading Up 2.8%</h2>
<div class="lb-trans"><h2>BeOne Medicines 股价上涨 2.8%</h2>
</div><p>Shares of ONC stock opened at $283.45 on Thursday. The company has a current ratio of 3.41, a quick ratio of 3.08 and a debt-to-equity ratio of 0.22. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $196.45 and a 12-month high of $385.22. The stock has a market capitalization of $31.10 billion, a P/E ratio of 112.48 and a beta of 0.53. The firm's 50 day moving average is $326.25 and its 200 day moving average is $327.68.</p>
<div class="lb-trans"><p>ONC 股票在周四开盘时为 283.45 美元。该公司的流动比率为 3.41，速动比率为 3.08，债务与股本比率为 0.22。BeOne Medicines Ltd. - Sponsored ADR 的 12 个月低点为 196.45 美元，12 个月高点为 385.22 美元。该股票的市值为 311 亿美元，市盈率为 112.48，贝塔系数为 0.53。该公司的 50 日移动平均线为 326.25 美元，200 日移动平均线为 327.68 美元。</p>
</div><p>BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing analysts' consensus estimates of $1.60 by ($1.02). The company had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. Research analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.</p>
<div class="lb-trans"><p>BeOne Medicines (NASDAQ:ONC - 获取免费报告) 最近在 2 月 26 日星期四公布了其财报。该公司报告本季度每股收益为 0.58 美元，低于分析师一致预期的 1.60 美元，差额为 1.02 美元。该公司本季度的收入为 15 亿美元，而分析师预期为 14.5 亿美元。BeOne Medicines 的净利润率为 5.37%，股本回报率为 10.70%。研究分析师预计 BeOne Medicines Ltd. - Sponsored ADR 在本年度将发布 -5.82 美元的每股收益。</p>
</div><h2>BeOne Medicines Profile</h2>
<div class="lb-trans"><h2>BeOne Medicines 概况</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.</p>
<div class="lb-trans"><p>BeOne Medicines Ltd. 是一家总部位于瑞士的全球肿瘤学公司，致力于发现和开发更具可负担性和可及性的创新治疗方案，以帮助全球癌症患者。该公司的产品组合涵盖血液学和实体肿瘤，BeOne 正在通过其内部能力和合作加速其多样化的新型治疗管线的开发。该公司由 Xiao Dong Wang 和 John V. Oyler 于 2010 年 10 月 28 日创立，总部位于瑞士巴塞尔。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than BeOne Medicines</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 BeOne Medicines</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ONC?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 ONC 股票吗？</strong> 访问 HoldingsChannel.com 获取 BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - 免费报告) 的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T05D" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ONC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BeOne Medicines Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 BeOne Medicines 吗？</h2>
</div><p>Before you consider BeOne Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 BeOne Medicines 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 BeOne Medicines 并不在名单上。</p>
</div><p>While BeOne Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 BeOne Medicines 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

JPMorgan Chase & Co. Sells 47,002 Shares of BeOne Medicines Ltd. - Sponsored ADR $ONC

Market Beat

Invesco Nasdaq Biotechnology ETF

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

医药突破 ETF - ALPS

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

百济神州

生物科技 ETF - VanEck Vectors

Defiance Daily Target 2X Long JPM ETF

摩根大通

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

摩根大通出售了 BeOne Medicines Ltd. - 赞助 ADR $ONC 的 47,002 股股份